These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 8603410)

  • 1. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo.
    Millauer B; Longhi MP; Plate KH; Shawver LK; Risau W; Ullrich A; Strawn LM
    Cancer Res; 1996 Apr; 56(7):1615-20. PubMed ID: 8603410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H
    Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant.
    Millauer B; Shawver LK; Plate KH; Risau W; Ullrich A
    Nature; 1994 Feb; 367(6463):576-9. PubMed ID: 8107827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flk-1 as a target for tumor growth inhibition.
    Strawn LM; McMahon G; App H; Schreck R; Kuchler WR; Longhi MP; Hui TH; Tang C; Levitzki A; Gazit A; Chen I; Keri G; Orfi L; Risau W; Flamme I; Ullrich A; Hirth KP; Shawver LK
    Cancer Res; 1996 Aug; 56(15):3540-5. PubMed ID: 8758924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model.
    Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Ikenaka Y; Noguchi R; Nakatani T; Tsujinoue H; Fukui H
    Hepatology; 2001 Apr; 33(4):841-7. PubMed ID: 11283848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.
    Siemeister G; Schirner M; Weindel K; Reusch P; Menrad A; Marmé D; Martiny-Baron G
    Cancer Res; 1999 Jul; 59(13):3185-91. PubMed ID: 10397264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.
    Geng L; Donnelly E; McMahon G; Lin PC; Sierra-Rivera E; Oshinka H; Hallahan DE
    Cancer Res; 2001 Mar; 61(6):2413-9. PubMed ID: 11289107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
    Prewett M; Huber J; Li Y; Santiago A; O'Connor W; King K; Overholser J; Hooper A; Pytowski B; Witte L; Bohlen P; Hicklin DJ
    Cancer Res; 1999 Oct; 59(20):5209-18. PubMed ID: 10537299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formation of transformed endothelial cells in the absence of VEGFR-2/Flk-1 by Polyoma middle T oncogene.
    Mühlner U; Möhle-Steinlein U; Wizigmann-Voos S; Christofori G; Risau W; Wagner EF
    Oncogene; 1999 Jul; 18(29):4200-10. PubMed ID: 10435633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma.
    Fine BA; Valente PT; Feinstein GI; Dey T
    Gynecol Oncol; 2000 Jan; 76(1):33-9. PubMed ID: 10620438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenesis in embryos and ischemic diseases.
    Breier G; Damert A; Plate KH; Risau W
    Thromb Haemost; 1997 Jul; 78(1):678-83. PubMed ID: 9198238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VEGFs, receptors and angiogenesis.
    Veikkola T; Alitalo K
    Semin Cancer Biol; 1999 Jun; 9(3):211-20. PubMed ID: 10343072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene.
    Belletti B; Ferraro P; Arra C; Baldassarre G; Bruni P; Staibano S; De Rosa G; Salvatore G; Fusco A; Persico MG; Viglietto G
    Oncogene; 1999 Aug; 18(34):4860-9. PubMed ID: 10490819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo.
    Ramakrishnan S; Olson TA; Bautch VL; Mohanraj D
    Cancer Res; 1996 Mar; 56(6):1324-30. PubMed ID: 8640821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Possible involvement of VEGF-FLT tyrosine kinase receptor system in normal and tumor angiogenesis.
    Shibuya M; Seetharam L; Ishii Y; Sawano A; Gotoh N; Matsushime H; Yamaguchi S
    Princess Takamatsu Symp; 1994; 24():162-70. PubMed ID: 8983073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma.
    Ng IO; Poon RT; Lee JM; Fan ST; Ng M; Tso WK
    Am J Clin Pathol; 2001 Dec; 116(6):838-45. PubMed ID: 11764072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma.
    Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Hicklin DJ; Huber J; Nakatani T; Tsujinoue H; Yanase K; Imazu H; Fukui H
    Hepatology; 2002 Apr; 35(4):834-42. PubMed ID: 11915029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers.
    Gunningham SP; Currie MJ; Han C; Robinson BA; Scott PA; Harris AL; Fox SB
    Clin Cancer Res; 2000 Nov; 6(11):4278-86. PubMed ID: 11106244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.